39 studies found for:    " October 05, 2011":" November 04, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
1 Terminated
Has Results
A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV
Conditions: Human Immunodeficiency Virus (HIV);   HIV Associated Neurocognitive Disorders (HAND)
Intervention: Drug: Raltegravir
2 Not yet recruiting A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac)
Conditions: Human Immunodeficiency Virus (HIV);   HIV Associated Neurocognitive Disorders (HAND)
Intervention: Drug: Maraviroc
3 Active, not recruiting A Commitment Device for Medication Adherence Among HIV Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV
Intervention: Other: Medication Adherence among HIV/AIDS Patients
4 Unknown  Maternal-fetal CD4 Microchimerism in HiV Exposed Newborns After Spontaneous Delivery and Cesarean Section
Condition: Human Immunodeficiency Virus
Intervention:
5 Completed Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
Condition: Human Immunodeficiency Virus (HIV)
Interventions: Drug: Darunavir/Ritonavir (DRV/r);   Drug: Lopinavir in fixed combination with Ritonavir;   Drug: Zidovudine;   Drug: NRTIs;   Drug: Efavirenz
6 Completed Problems With Immune Recovery in the Gut Tissue
Condition: Human Immunodeficiency Virus
Intervention: Procedure: Genital and rectal swabbing
7 Active, not recruiting Tissue Drug Levels of HIV Medications
Condition: Human Immunodeficiency Virus
Intervention: Drug: Initiation of anti-retroviral therapy
8 Active, not recruiting
Has Results
Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: dolutegravir 50 mg OAD;   Drug: darunavir 800mg OAD;   Drug: ritonavir 100mg OAD
9 Completed A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects
Condition: Infections, Human Immunodeficiency Virus and Hepatitis
Interventions: Drug: Dolutegravir;   Drug: Rlipivirine;   Drug: GSK1265744
10 Completed Atazanavir/Ritonavir and Zinc Pharmacokinetic Study
Condition: HIV Infection
Interventions: Drug: 1 Solvazinc tablet, day 2 to day 15;   Drug: 1 Solvazinc tablet, day 15 to day 28
11 Completed Intranasal Modified Vacc-4x Gag Peptides With Endocine as Adjuvant
Condition: HIV Infection
Interventions: Biological: Vacc-4x low dose;   Biological: Vacc-4x medium dose;   Biological: Vacc-4x high dose;   Biological: Zero dose
12 Withdrawn Trial of Probiotics to Lower Microbial Translocation and Immune Activation in HIV-Infected Adolescents
Condition: HIV Infection
Interventions: Dietary Supplement: Probiotics;   Dietary Supplement: Placebo
13 Recruiting Early Antiviral Therapy for Critically Ill HIV Infected Patients
Condition: HIV Infection
Interventions: Drug: early HAART;   Drug: Late HAART
14 Recruiting RAltegravir Switch STudy: Effects on Endothelial Recovery
Conditions: HIV Infection;   Endothelial Dysfunction
Intervention: Drug: raltegravir
15 Completed Efficacy of Raltegravir in a Large Urban HIV Clinical Population in Milan
Condition: HIV Infections
Intervention:
16 Completed Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study.
Condition: Infections, Human Immunodeficiency Virus and Hepatitis
Interventions: Drug: Dolutegravir;   Drug: Methadone
17 Completed Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV
Condition: HIV Infection
Intervention:
18 Completed Influence of Antiretroviral Regimen on Immune Reconstitution in the Female Genital Tract
Conditions: Women's Health;   HIV Infection;   Genital Diseases, Female
Intervention:
19 Active, not recruiting Evaluating the Effectiveness of the Quadrivalent Human Papillomavirus (HPV) Vaccine at Preventing Anal HPV Infection in HIV-Infected Men and Women
Condition: HIV Infections
Interventions: Biological: Quadrivalent HPV Vaccine;   Biological: Placebo Vaccine for Male Participants Only;   Biological: Placebo Vaccine for Female Participants Only
20 Completed A Study of MK-1439 in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005)
Condition: HIV-1 Infection
Interventions: Drug: MK-1439;   Drug: Placebo

Previous Page Studies Shown (1-20) Next Page (21-39) Show next page of results
Indicates status has not been verified in more than two years